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therapies, but the superiority of this approach remains to be 
proven. Future strategies to reduce the burden of acute stroke 
in Europe should focus on immediate access to acute stroke 
care and dedicated stroke units for all patients.
 © 2014 S. Karger AG, Basel 
 Introduction 
 Stroke will affect one in six people during their life-
times  [1] and is the most frequent cause of disability in 
adults. For the treatment of ischemic stroke, several re-
canalization therapies have emerged during the last de-
cades: intravenous thrombolysis (IVT), intra-arterial 
treatment (IAT) comprising local thrombolysis and me-
chanical procedures, bridging of IVT and IAT, and ultra-
sound-enhanced thrombolysis. Up to now, only IVT with 
recombinant tissue plasminogen activator (rtPA), stroke 
unit management, early aspirin therapy and decompres-
sive craniotomy have demonstrated their efficacy in an 
evidence-based manner. Despite the clear positive evi-
dence, however, only about 3% of European stroke pa-
tients received IVT in 2005  [2] . Insufficient public aware-
ness of stroke symptoms, delayed diagnosis, and the ab-
sence of stroke networks or treatment availability are 
probably the major reasons for the low application of IVT 
for acute stroke patients. 
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 Abstract 
 Background: Stroke affects one in six people throughout 
their lifetimes and is the most frequent cause of disability in 
adults. Several recanalization therapies have emerged and 
the management of patients in stroke units has improved over 
the last decades.  Summary: This article examines the current 
treatment options for stroke patients, summarizing the key 
clinical evidence, as well as listing the complications and prac-
tical issues related to each of these main treatment options. 
 Key Messages : Recent advances in the treatment of acute 
stroke include developments in intravenous thrombolysis 
(IVT), intra-arterial treatment and bridging therapies. Clinical 
Implications: Treatment within a stroke unit reduces mortal-
ity and disability regardless of age, sex and stroke severity. IVT 
is widely available and reduces disability when initiated with-
in 4.5 h after the onset of symptoms. The major limitations of 
IVT are the low recanalization rates and the narrow time frame. 
Intra-arterial treatment, especially when using newly devel-
oped stent-retrievers, achieves very high recanalization rates. 
It is restricted by its limited availability and by the longer time 
span required to initiate therapy. Bridging both therapies is a 
promising approach that combines the advantages of both 
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 This article will review the current treatment options 
for acute ischemic stroke with special emphasis on patient 
selection and treatment strategy. 
 Stroke Unit Management 
 Stroke unit care of thrombolyzed patients and conser-
vatively treated patients has been investigated in several 
trials, which have showed that it reduces both stroke-re-
lated complications and mortality (OR 0.86, 95% CI: 
0.76–0.98, p = 0.02), shortens the hospitalization time and 
improves outcomes (OR 0.82, 95% CI: 0.73–0.92, p = 
0.001 for death or dependency)  [3, 4] . 
 Blood Pressure Control 
 Approximately 60–80% of stroke patients present with 
arterial hypertension >140/90 mm Hg upon admission. 
Several potential underlying mechanisms have been im-
plicated, such as elevated intracranial pressure, decreased 
parasympathetic activity, stress, compensatory mecha-
nisms, or injury to autonomic control systems in the 
brain stem. Nevertheless, a recent study suggests that the 
elevation of blood pressure in the acute phase compared 
to the premorbid condition is lower than expected (an 
increase of 10.6 mm Hg against the 10-year mean pre-
morbid level)  [5] . Hypertension during IVT is associated 
with a higher risk for symptomatic intracerebral hemor-
rhage (sICH)  [6–8] . Systolic blood pressure above 185 
mm Hg or diastolic pressure above 105 mm Hg should be 
carefully lowered (e.g., with the use of nicardipine or la-
betalol) before initiating IVT, and then monitored every 
15 min during IVT, every 30 min for 6 h post-IVT, and 
then hourly until 24 h after rtPA treatment. 
 In conservatively treated patients, blood pressure is 
recommended to be carefully lowered when systolic pres-
sure is above 220 mm Hg or diastolic pressure above 110 
mm Hg, although lowering the blood pressure was not 
associated with better outcomes according to a Cochrane 
Review or the more recently published SCAST or CATIS 
trials  [9–11] . There seems to be a U-shaped association 
between BD and mortality in the periprocedural period: 
an increase in mortality of 3.8 or 17.9% was found for ev-
ery 10 mm Hg change above or below 150 mm Hg  [12] . 
 Glucose Control 
 Elevated glucose levels are associated with poorer out-
comes during the acute phase  [13, 14] , but a meta-analy-
sis did not identify a clear benefit of strict glycemic con-
trol at 90 days (a benefit was only seen at 30 days), but 
found a 14% risk of hypoglycemia in patients with strict 
glycemic control  [15] . Nevertheless, it is recommended to 
avoid glucose levels >11 mmol/l  [16] .
 Temperature Control 
 Elevated temperatures should be lowered if above 
37.5  °  C  [16] . 
 Mobilization 
 There is an ongoing debate about the best time point 
to initiate mobilization: early (within 24 h after hospital-
ization) or delayed mobilization. Two recent randomized 
controlled trials revealed contrary results, one favoring 
early mobilization and one delayed mobilization  [17, 18] . 
A Cochrane review concluded that the data are insuffi-
cient to support early or delayed mobilization  [19] . 
 Antiplatelet Therapy 
 Aspirin has been the established standard treatment 
for acute ischemic stroke since two independent trials 
showed improved outcomes of at least 1 of 1,000 stroke 
patients  [20, 21] .
 Dual antiplatelet therapy appears to reduce the risk of 
recurrent stroke over monotherapy, but the increased 
bleeding risk outweighs the beneficial effects when ad-
ministered over a longer time period  [22, 23] . However, 
there is growing evidence that the benefits outweigh the 
risk of bleeding if dual antiplatelet therapy is given over a 
limited timeframe. A recent Chinese study found that the 
use of aspirin plus clopidogrel to be superior to a small 
(75 mg) dose of aspirin alone in the prevention of early 
stroke recurrence after transient ischemic attack (TIA) 
and minor ischemic stroke when given over a timeframe 
of three months  [24] . In symptomatic intracranial steno-
sis, dual antiplatelet therapy was more effective at reduc-
ing microembolic signals than aspirin alone, and dual an-
tiplatelet therapy over a limited period of 3 months proved 
to be superior to stenting with Wingspan stent  [25, 26] .
 Intravenous Thrombolysis 
 Intravenous thrombolysis with rtPA applied within 
3 h of stroke onset proved to be an effective treatment for 
acute ischemic stroke in the NINDS and ECASS II trials 
 [27, 28] . The ECASS III trial then extended the indication 
to 4.5 h post-stroke for patients younger than 80 years, 
with National Institutes of Health Stroke Scale (NIHSS) 
scores below 25 and without diabetes mellitus or previous 

















   
   
   
   
   
   
   
   



















 Jung/Stapf/Arnold  Eur Neurol 2015;73:98–105
DOI: 10.1159/000365210
100
 Besides recanalization, the elapsed time to treatment 
turned out to be one of the most important predictors of 
outcome in several trials. This is reflected in the ratio of the 
number of patients that need to be treated in order to pre-
vent one patient from death or disability, that rises from 3 
when therapy is initiated within 1.5 h after stroke onset, to 
7 when therapy is initiated between 1.5 and 3 h after stroke 
onset, up to 14 when initiated between 3 and 4.5 h after 
stroke onset. 
 Complications  
 Most instances of sICH occur within 24–36 h after 
treatment, with a frequency of 7% (95% CI: 5.2–8.7%) in 
large trials  [30] . Older patients, patients with high base-
line NIHSS scores, those with arterial hypertension, dia-
betes mellitus, hyperglycemia, atrial fibrillation, and signs 
of early infarct demarcation on CT or MRI are at a high-
er risk for sICH  [31, 32] .
 Treating Patients with Stroke Mimics  
 It is unavoidable that a few patients with stroke mimic 
conditions (such as epileptic seizures or metabolic dis-
ease) receive IVT before the correct diagnosis can be es-
tablished. Fortunately, the use of IVT in patients with 
stroke mimics is rarely associated with complications: a 
recent multicenter cohort study found a 1% sICH rate af-
ter IVT in patients with conditions that mimic stroke 
 [33] .
 Restrictions  
 The major restrictions of IVT are the short treatment 
window and relatively low recanalization rates in pa-
tients with proximal vessel occlusions  [34, 35] , high 
 NIHSS score  [36] and thrombus lengths of more than 
8 mm  [37] .
 Practical Issues  
 Recommended exclusion criteria for IVT are listed in 
 table 1 . For routine treatment, 10% of the standard dosage 
of 0.9 mg/kg body weight is applied as a bolus, followed 
by the remaining 90% administered over 60 min. Therapy 
initiation should not be delayed by waiting for laboratory 
results  [38] . 
 Intra-Arterial Treatment 
 The PROACT II trial was one of the first intra-arterial 
thrombolysis (IAT) trials, and showed better outcomes 
with intra-arterial prourokinase application together 
with low dose heparin, compared to low-dose heparin 
alone in patients with middle cerebral artery occlusions 
treated within 6 h after stroke onset  [39] . Since then, sev-
eral mechanical techniques have been developed for 
thrombus disruption, stenting, and thrombectomy (see 
Gralla et al., 2012 for a detailed overview)  [40] in large 
vessel occlusions. Most trials included patients within 8 h 
of symptom onset. The embolectomy devices that were 
used in the MERCI and Multi-MERCI trials or the Pen-
umbra pivotal trial resulted in higher recanalization rates 
compared to local prourokinase application (successful 
recanalization in 46, 57.3, and 81.6% for each trial, respec-
tively)  [41–43] .
 The latest developments in the field of mechanical 
thrombectomy are stent retrievers. The SWIFT trial 
found higher rates of TIMI 2–3 recanalization (89 vs. 
67%) and mRS outcomes of 0–2 (58 vs. 33%) with the use 
of the solitaire device compared to the MERCI retriever 
(see  fig. 1 )  [44] . The TREVO 2 trial found a Thrombolysis 
in Cerebral Infarction (TICI) 2–3 recanalization in 92% 
of the patients with the Trevo retriever  [45] . 
 The SYNTHESIS trial compared endovascular treat-
ment with IVT in patients treated within 4.5 h after symp-
tom onset and found no superiority of IAT over IVT with 
regards to the frequency of excellent outcomes (mRS 0–1) 
 [46] . However, these results may have been biased by a 
1 h longer median time from stroke to treatment in the 
IAT group, the inclusion of patients without vessel occlu-
Table 1.  Inclusion criteria for intravenous thrombolysis
Absolute
CT or MRI evidence of intracranial hemorrhage
Relative
Gastrointestinal or urinary tract hemorrhage in previous 21 days
Major surgery in previous 14 days
Myocardial infarction in previous 3 months
Head trauma of prior stroke in previous 3 months
Blood pressure persistently elevated >185 mm Hg systolic and 
>105 mm Hg diastolic
Acute trauma (fracture)
International normalized ratio >1.7
Platelet count ≤100,000/mm3
Blood glucose ≤50 mg/dl
CT evidence of large infarction (>1/3 of middle cerebral artery 
territory)
Rapidly resolving or minor and isolated deficits
Severely affected patients
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sion, and intra-arterial treatment of patients without ves-
sel occlusion. Moreover, stent retrievers were used in a 
minority of patients. 
 Complications 
 sICH is observed in 4.5–10.5% of treated patients  [30] . 
Rarer complications include aneurysm of the femoral ar-
tery, distal embolus dislocation, and intracranial artery 
dissection or rupture. 
 Restrictions 
 The major restriction of IAT is the delay in the time to 
start of treatment, as compared to IVT. Formally, clinical 
efficacy has been proven only in a single randomized con-
trolled trial including patients with M1 or M2 middle ce-
rebral artery occlusion  [39] .
 Practical Issues  
 In many stroke centers, IAT is considered in patients with 
proximal vessel occlusions that can be treated within 8 h of 
symptom onset. It may also be considered in patients with 
basilar artery occlusions beyond 8 h of symptom onset  [47] . 
There is an ongoing debate on whether performing IAT 
 under general anesthesia is safe, because three retrospec-
tive studies revealed less favorable outcomes for patients un-
dergoing this procedure under general anesthesia  [48–50]. 
 Bridging Therapy 
 Bridging IVT and IAT is theoretically a win–win con-
cept, because those patients who recanalize with IVT ben-
efit from early recanalization and those with persistent 
vessel occlusion despite IVT benefit from the higher 
chance for recanalization with IAT.
 The expected higher recanalization rates with bridging 
therapy compared to IVT alone were indeed demonstrat-
ed in the randomized controlled IMS III trial  [51] and the 
RECANALISE study  [52] . A recent meta-analysis esti-
mated a pooled recanalization rate of 69.6% (95% CI: 
63.9–75%) in 559 patients treated with bridging therapy 
 [53] . Whether or not bridging therapy improves out-
comes over IVT alone is less clear. Although the IMS II 
trial found better outcome scores (measured by the Bar-
thel Index) in patients treated with bridging therapy com-
pared to patients in the NINDS trial, neither the prospec-
tive RECANALISE study, nor the IMS III trial showed 
significant differences in functional outcomes  [51, 52] . 
The IMS III trial only showed a clear trend in favor of 
bridging therapy compared to IVT alone in patients with 
NIHSS score >20 (p = 0.06). Unfortunately, in the IMS III 
trial, the new stent retrievers were used in only a very 
small number of patients and time delays between IVT 
and IAT were longer than in previous studies  [54, 55] . 
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Nevertheless, the efficacy of bridging therapy with stent 
retrievers remains to be demonstrated in ongoing trials, 
such as the SWIFT-PRIME study  [56] . 
 Complications 
 The combined use of IVT and IAT is associated with 
acceptable rates of sICH, reported as 8.6% (95% CI: 6.8–
10.6%) in a recent meta-analysis  [53] and 6.2% in the IMS 
III trial  [51] .
 Restrictions 
 Compared with IVT, the major restriction is the lack 
of efficacy demonstrated in randomized controlled trials.
 Practical Issues  
 IVT with rtPA can be performed either with the stan-
dard dosage (0.9 mg/kg body weight) or with a reduced 
2/3 dosage (0.6 mg/kg body weight). There are no ran-
domized controlled trials that compared the two dosages 
but a meta-analysis found a similar safety profile along-
side better functional outcomes in patients treated with 
the full dose  [57] . The ongoing ENCHANTED trial will 
address the issue of appropriate rtPA dosing in a prospec-
tive randomized study design (NCT01422616).
 Table 2 summarizes the advantages and disadvantages 
of IVT, intra-arterial treatment and bridging therapy. 
 Ultrasound-Enhanced Thrombolysis  
 Three different ultrasound-based approaches to im-
proving recanalization success have been tested in ran-
domized controlled trials. In the CLOTBUST trial, use of 
a 2 MHz transcranial Doppler led to a higher rate of com-
plete recanalization or dramatic clinical recovery within 
2 h after administration of rtPA, compared to rtPA alone 
(49 vs. 30%) with a low rate of complications  [58] .
 A randomized trial with low frequency (300 kHz) 
higher intensity (700 mW/cm  [2] ) ultrasound had to be 
terminated due to increased rates of sICH in patients 
treated with ultrasound  [59] . Three randomized con-
trolled trials tested the addition of microbubbles to ultra-
sound together with rtPA versus rtPA alone, and found 
higher recanalization rates in the ultrasound-treated pa-
tients  [60–62] .
 A final conclusion regarding the efficacy of ultra-
sound-enhanced thrombolysis cannot be made based on 
the available data, and we recommend using this ap-
proach only in the setting of clinical trials. 
 Decompressive Craniotomy for Malignant Stroke 
 Anterior Circulation Strokes 
 Three randomized controlled trials (DECIMAL, 
 DESTINY, HAMLET) examined the effect of early de-
compressive surgery within 48 h after stroke onset in 
patients with space-occupying infarction of the middle 
cerebral artery territory and who were younger than 
55 or 60 years  [63–66] . Early decompressive cranioto-
my  was associated with reduced mortality and an in-
creased  number of patients with favorable outcomes. 
The DESTINY II study included patients with space-
occupying infarcts of the middle cerebral artery terri-
tory who were older than 60 years. The study results 
showed a significant decrease in 1-year mortality (43 vs. 
76%), but the majority of survivors (89%) remained se-
verely handicapped  [67] .
Table 2.  Advantages and disadvantages of the main acute stroke treatment options
Intravenous therapy Intra-arterial therapy  Bridging




High recanalization in distal 
artery occlusion
High recanalization rates in proximal 
occlusions
Fast recanalization with new 
thrombectomy devices after beginning 
of angiography
Fast initiation of 
intravenous therapy
High recanalization rates 
with IAT also in 
proximal occlusions
Disadvantages Low recanalization rates of 
proximalocclusions, high 
NIHSS or thrombus lengths 
above 8 mm Short time window
Usually long time interval to therapy
initiation
Available only in specialized centers
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 Complications  
 Infections and bleeding are the most frequent compli-
cations. In rare cases with large decompressions, the so-
called sinking skin flap syndrome can complicate reha-
bilitation  [68] . 
 Practical Issues  
 The best time point for performing decompressive 
surgery in space-occupying infarctions is unknown, but 
most trial protocols performed craniotomy as early as 
possible. If it is likely that decompressive surgery is nec-
essary (as for young patients with very large infarc-
tions), it should be performed as early as possible. In 
patients for whom the situation is less clear, many stroke 
centers perform surgery in case of clinical deterioration. 
In the case of threatening malignant infarcts and be-
fore surgery, the upper part of the body should be ele-
vated to >30°. Bone reimplantation is usually performed 
2–3 months after stroke, but this practice varies between 
centers. 
 Posterior Circulation Strokes 
 In patients with massive cerebellar infarction, close 
neurological monitoring is mandatory. Despite the lack 
of controlled trials, decompressive surgery should be con-
sidered in patients with complete territorial infarction or 
infarction of more than 2/3 of the cerebellar hemisphere, 
beginning hydrocephalus due to herniation, shift of the 
fourth ventricle, or early clinical signs of brainstem com-
pression.
 Recanalization in Patients not Fulfilling the Criteria 
of the Current Guidelines 
 Patients with wake-up stroke, beyond 6 h, elderly pa-
tients, and patients under oral anticoagulation therapy 
are usually not considered for recanalization therapies, 
but they can be considered on an individual basis. 
 Patients with Wake-Up Stroke and Treatment Beyond 
6 h  
 In wake-up stroke with a last-seen normal time longer 
than 4.5 h, or in cases of stroke with unclear symptom 
onset or those beyond 6 h, IAT can be considered in case 
of large vessel occlusions  [69–71] . Whether these patients 
benefit from therapy is not known. Patients with exten-
sive early signs of infarction on CT or MR imaging should 
probably not be treated. There are ongoing trials (for 
wake-up stroke and non-wake-up stroke) that select pa-
tients on the basis of MR-based perfusion-diffusion-mis-
match finding. At the moment, it is unclear if patient se-
lection upon mismatch improves therapy outcome. Sev-
eral randomized clinical trials are currently underway to 
address this issue (AWOKE, NCT01150266; SAIL-ON, 
NCT01643902; WAKE-UP, NCT01525290; WAKE-UP 
STROKE, NCT01183533).
 Elderly Patients  
 Most acute stroke treatment trials have excluded pa-
tients older than 80 years. Data from non-randomized 
studies imply that IVT and IAT can be performed safe-
ly in the elderly, but outcomes were less favorable when 
compared to younger patients. Two recent trials found 
an at least comparable or even better treatment effect 
of  IVT in the elderly compared to younger patients 
 [36, 72] . Therefore, the poorer outcomes in the elderly 
may be a general reflection of the outcomes in the el-
derly population as a whole, and as already observed 
in  untreated stroke patients. Nevertheless, elderly pa-
tients should be considered for therapy on an individu-
al basis.
 Patients Under Oral Anticoagulation  
 IAT may be considered in patients under oral antico-
agulation (INR >1.7) who have large vessel occlusions. 
One retrospective case series found no increased risk for 
sICH in 28 patients under anticoagulation therapy who 
were treated with IAT  [73] .
 Future Perspectives 
 The main challenges in the field of acute ischemic 
stroke therapy are to increase the number of patients 
who can benefit from thrombolysis and the improvement 
of patient selection for IVT, IAT and bridging therapy. 
Furthermore, phase II trials indicate that alternative 
thrombolytic agents, such as Tenecteplase, Desmoteplase, 
or Reteplase may provide effective treatment alterna-
tives. Ongoing trials will hopefully answer the question 
on whether hypothermia is as effective in stroke patients 
as it is in cardiac patients (EuroHYP-1 [NCT01833312], 
 ICTuS2/3 [NCT01123161], ReCCLAIM II [NCT0172 
8649]).
 Disclosure Statement 
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